NCT04844528View on ClinicalTrials.gov

Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia (CLL) With History of Non-melanoma Skin Cancers (NMSC)

PHASE2RecruitingINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

February 25, 2022

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2028

Conditions
Chronic Lymphocytic LeukemiaNon-melanoma Skin Cancer (NMSC)
Interventions
DRUG

Nicotinamide

Oral nicotinamide 500 mg twice daily (BID).

DRUG

Placebo

Oral placebo twice daily for the first year.

Trial Locations (1)

84112

RECRUITING

Huntsman Cancer Institute at University of Utah, Salt Lake City

All Listed Sponsors
collaborator

Huntsman Cancer Institute

OTHER

lead

University of Utah

OTHER